Mapping the tumor budding and its microenvironment in colorectal cancer using hyperplex immunofluorescence
Current colon cancer classification, prognostication, and therapy decisions are based mainly on cancer staging. However, additional biomarkers are needed to improve patient stratification and treatment decision-making strategies. Tumor budding (TB) is recognized as an independent prognostic factor in a variety of solid cancers. In this study we present the development of a multiplex immunofluorescence (mIF) panel for spatial characterization of TB and the tumor microenvironment.
Watch this webinar to discover how:
- mIF can be automated on the COMET™ platform using only non-conjugated primary antibodies
- mIF can streamline the extraction of valuable TB features in terms of marker expression
- TB phenotypes and their cellular neighborhood can help identify and better define their therapeutic potential for a personalized medicine approach.
- Dr. Cansaran Saygili Demir, University of Bern
- Bastian Nicolai, Lunaphore